|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside显示文摘MicroRNAs(miRNAs) are small, single-stranded, noncoding RNAs that can post-transcriptionally regulate the expression of various oncogenes and tumor suppressor genes. Dysregulated expression of many miRNAs have been shown to mediate the signaling pathways critical in the multistep carcinogenesis of colorectal cancer(CRC). MiR NAs are stable and protected from RNase-mediated degradation, thereby enabling its detection in biological fluids and archival tissues for biomarker studies. This review focuses on the role and application of miRNAs in the prognosis and therapy of CRC. While stage Ⅱ CRC is potentially curable by surgical resection, a significant percentage of stage Ⅱ CRC patients do develop recurrence. MiRNA biomarkers may be used to stratify such high-risk population for adjuvant chemotherapy to provide better prognoses. Growing evidence also suggests that miRNAs are involved in the metastatic process of CRC. Certain of these miRNAs may thus be used as prognostic biomarkers to identify patients more likely to have micro-metastasis, who could be monitored more closely after surgery and/or given more aggressive adjuvant chemotherapy. Intrinsic and acquired resistance to chemotherapy severely hinders successful chemotherapy in CRC treatment. Predictive miRNA biomarkers for response to chemotherapy may identify patients who will benefit the most from a particular regimen and also spare the patients from unnecessary side effects. Selection of patients to receive the new targeted therapy is becoming possible with the use of predictive miRNA biomarkers. Lastly, forced expression of tumor suppressor miRNA or silencing of oncogenic miRNA in tumors by gene therapy can also be adopted to treat CRC alone or in combination with other chemotherapeutic drugs. | Kenneth KW To Christy WS Tong Mingxia Wu William CS Cho | 2018 | World Journal of Gastroenterology2018，24，27： | 29 |
| 2 | Aberrant promol er methylation of the ABCG2 gene in renal carcino ma显示文摘 | Kenneth KW Zhan Z Susan EB | 2006 | MolCellBiol2006，26，22： | 1 |
| 3 | Radiological prognosticators of hepatocellular carcinoma treated by hepatectomy显示文摘BACKGROUND: Hepatectomy is the main curative treatment for hepatocellular carcinoma (HCC), but postoperative long- term survival is poor. Preoperative radiological features of HCC displayed by computed tomography or magnetic resonance imaging could serve as additional prognostic factors. This study aimed to identify preoperative radiological features of HCC that may be of prognostic significance in hepatectomy. METHODS: Ninety-two patients who underwent hepatectomy for HCC were included in this study. Preoperative radiological features including tumor number, size, location (peripheral, middle, central), portal vein invasion, hepatic vein invasion, and presence of pseudo-capsule were analyzed in relation to survival. RESULTS: With a median follow-up period of 41.7 months, the 1-, 3- and 5-year overall survival rates were 85%, 65% and 58%, respectively. Univariate analysis showed that portal vein invasion and absence of pseudo-capsule were significant prognostic factors for overall survival, while all the examined radiological features were prognostic factors for disease-free survival. Multivariate analysis for overall survival found no significant factor. On multivariate analysis for disease-free survival, patients who had tumors with portal vein invasion had poorer survival with a hazard ratio of 2.26 (95% CI, 1.05-4.91; P=0.038) and patients with single nodular HCC or pseudo-capsulated HCC had better survival with a hazard ratio of 0.50 (95% CI, 0.27-0.94; P=0.032) and 0.38 (95% CI, 0.14-0.99; P=0.048), respectively. CONCLUSIONS: Demonstrable pseudo-capsule of HCC and solitary HCC on imaging and absence of portal vein invasionare features associated with better disease-free survival after hepatectomy. These features may guide treatment planning for HCC. | Kevin KW Chu See Ching Chan Sheung Tat Fan Kenneth SH Chok Tan To Cheung William W Sharr Albert CY Chan Chung Mau Lo | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，6： | 1 |
| 4 | Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin显示文摘 | Kenneth KW Wang XN Yu Ch W | | 0，，： | 1 |
| 5 | Chemoprevention of esophageal adencarcinoma by COX-2 inhibitors in an animal model of Barrett' s esophagus显示文摘 | Buttar NS Kenneth KW Leontovich O | 2002 | Gastroenterology2002，122，： | 1 |
| 6 | Thrombomodulin Ala455Val Polymorphism and Risk of Coronary Heart Disease显示文摘 | Aleksic N Chul A | 2001 | Circulation2001，103，： | 1 |
| 7 | Interaction between soluble thrombomodulin and intercellar adhesion molecule - 1 in predicting risk of coronary heart disease 显示文摘 | Kenneth KW Aleksic N Ballantyne C | 2003 | Circulation2003，107，4： | 1 |
| 8 | Suppression of HIF - 1α transcriptional activity by the HIF prolyl hydroxylase EGLN1 显示文摘 | Kenneth KW Huang LE Huang E | 2005 | J Biol Chem2005，280，38： | 1 |
| 9 | Endoscopic therapy for Barrett's esophagus and early esophageal adenocarcinoma 显示文摘 | Cadman LL Emmanuel CG Kenneth KW | 2013 | Gastroenterology clinics of North America2013，42，1： | 1 |
| 10 | Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery 显示文摘 | Yu TT Kenneth KW Alvert HL | 2016 | Colloids and surfaces B:biointerfaces2016，139，1： | 1 |
| 11 | Interaction between soluble thrombomodulin and intercellar adhesion molecule-1 in predicting risk of coronary heart disease显示文摘 | Kenneth KW Aleksic N Ballantyne C | 2003 | Circulation2003，107，4： | 1 |
| 12 | Circumvention of multidrug resistance of cancer cells by Chinese herbal medicines显示文摘 | Stella Chai Kenneth KW To Ge Lin | 2010 | Chine Med2010，5，： | 1 |
| 13 | Determination of the release of hydrolyzed demethylcantharidin from novel traditional Chinese medicine-platinum co-mpounds with anticancer activity by gas chromatography显示文摘 | Kenneth KW Ho Y P Steve C F | 2002 | J ChromatogrA2002，947，2： | 1 |
| 14 | Interaction between soluble Thrombombulin and intercellar adhesion molecule-1 in predicting risk of coronary heart disease显示文摘 | Kenneth KW Aleksic N Ballantyne C et a1 | 2003 | Circulation2003，107，4： | 1 |
| 15 | Treatment of type 2 diabetic patients with kidney disease with AT1-receptor antagonists: lessons from recent trials显示文摘 | William FK Kiyoshi K Paulette AL Shahnaz S Thomas PS Kenneth KW | 2002 | Clin Exp Nephrol2002，6，： | 1 |
| 16 | Aberrant promoter methylation of the abcg2 gene in renal carcinoma显示文摘 | Kenneth KW Zhan Z Susan EB | 2006 | Mol Cell Biol2006，26，22： | 1 |
| 17 | Emergency ABO-incompatible living donor liver transplant for patients with ultrahigh MELD scores显示文摘To the Editor:A 49-year-old Chinese man with treatment-naive chronic hepatitis B presented with a one-week history of jaundice when admitted to our hospital.On admission,his bilirubin was 704μmol/L,alanine aminotransferase 180 U/L,international normalized ratio 2.4,creatinine 140μmol/L,and Model for End-stage Liver Disease(MELD)score 35.His serum HBV DNA was 64.7 IU/mL,and he was commenced on entecavir.Nonetheless,he developed acute-onchronic liver failure on day 28 with grade 2 hepatic encephalopathy and a MELD score of 40(bilirubin 709μmol/L,international normalized ratio 3.3,creatinine 181μmol/L). | Kevin KW Chu Kenneth SH Chok James YY Fung Albert CY Chan Wing Chiu Dai Chung Mau Lo | 2019 | Hepatobiliary & Pancreatic Diseases International2019，18，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员